W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

News

06 March, 2025

Position of the Transparency Council – Fasenra (benralizumab)

13 January, 2025

Communication from AOTMIT on submission of PICO information for joint clinical assessment

27 March, 2025

Position of the Transparency Council – Reblozyl (luspatercept)

27 March, 2025

Position of the Transparency Council – Erwinase (crisantaspasum)

27 March, 2025

Position of the Transparency Council – Cartilage regeneration procedures using the AMIC technique

26 March, 2025

Opinion of the President – Program for the prevention and early detection of overweight and obesity among children and adolescents in the Piaseczno district for the years 2025-2027

26 March, 2025

Opinion of the President – Health policy program for therapeutic rehabilitation of Brzeg municipality residents for 2025-2028

26 March, 2025

Opinion of the President – Prevention of depressive disorders for children and adolescents aged 12-15 in the municipality of Józefów for 2025-2026

26 March, 2025

Opinion of the President – Program for the prevention and early detection of visual impairments for third-grade primary school students located in the city of Będzin for the years 2025-2027

24 March, 2025

The Transparency Council meeting 13/2025 on 31 March 2025

21 March, 2025

Status of work in March

21 March, 2025

Publication AWA

20 March, 2025

Opinion of the Transparency Council – netupitant + palonosetron

20 March, 2025

Opinion of the Transparency Council – sulfamethoxazolum + trimethoprimum

20 March, 2025

Position of the Transparency Council – Briumvi (ublituximab)

18 March, 2025

The Transparency Council meeting 12/2025 on 24 March 2025

18 March, 2025

Recommendation of the President – Fasenra (benralizumab)

18 March, 2025

Tariff Council meeting 3/2025 on 20 March 2025

14 March, 2025

The Transparency Council meeting 11/2025 on 17 March 2025 update

14 March, 2025

Publication AWA

13 March, 2025

Recommendation of the President – MMA/PA Anamix Infant, MMA/PA Anamix Junior, MMA/PA gel, MMA/PA Express 15, MMA/PA Cooler 15

13 March, 2025

Opinion of the Transparency Council – tacrolimusum

13 March, 2025

Opinion of the Transparency Council – sirolimusum

13 March, 2025

Opinion of the Transparency Council – posaconazole

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑